- All
- Product Management
- News
- Introduction
- Enterprise outlets
- FAQ
- Enterprise Video
- Enterprise Atlas
Chuangyuan Biotechnology has been granted a national invention patent for its research on proprietary strains.
On November 29, 2024, the invention patent certificate for "Lacticaseibacillus rhamnosus for Improving Lipid Metabolism and Its Application" (Patent No.: ZL 202411187281.6), independently developed and applied by Tianjin Chuangyuan Biotechnology Co., Ltd., was issued by the National Intellectual Property Administration.
The invention provides a Lacticaseibacillus rhamnosus for improving lipid metabolism and its application, relating to the field of microbiology. The name of the Lacticaseibacillus rhamnosus is IOB820, classified as Lacticaseibacillus rhamnosus.Lacticaseibacillus rhamnosus, preserved in the General Microbiology Center of the China Microbial Culture Collection Management Committee on April 3, 2019, abbreviated as CGMCC, with preservation number CGMCC No.17522. According to animal experiments, this strain promotes the β-oxidation of fatty acids by efficiently upregulating the mRNA expression of carnitine palmitoyltransferase 1, regulates lipid metabolism, alleviates inflammation symptoms in mice, and can reduce the levels of TNF-α, IL-1β, and IL-6 in high-fat mice, thereby inhibiting chronic low-grade inflammation associated with lipid metabolism disorders and improving the imbalance of intestinal flora caused by lipid metabolism disorders.
Related News